Frank P. Kroon

5.8k total citations · 1 hit paper
87 papers, 3.8k citations indexed

About

Frank P. Kroon is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Frank P. Kroon has authored 87 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Infectious Diseases, 37 papers in Epidemiology and 29 papers in Virology. Recurrent topics in Frank P. Kroon's work include HIV/AIDS drug development and treatment (28 papers), HIV Research and Treatment (27 papers) and HIV/AIDS Research and Interventions (24 papers). Frank P. Kroon is often cited by papers focused on HIV/AIDS drug development and treatment (28 papers), HIV Research and Treatment (27 papers) and HIV/AIDS Research and Interventions (24 papers). Frank P. Kroon collaborates with scholars based in Netherlands, United States and United Kingdom. Frank P. Kroon's co-authors include Jaap T. van Dissel, J.C. de Jong, R. van Furth, L. B. S. Gelinck, Mark de Boer, Tjitske de Boer, Tom H. M. Ottenhoff, Inez-Anne Haagen, Jean‐Laurent Casanova and Peter Kabel and has published in prestigious journals such as Science, The Journal of Experimental Medicine and PLoS ONE.

In The Last Decade

Frank P. Kroon

87 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Severe Mycobacterial and Salmonella Infections in Interleukin-12 Receptor-Deficient Patients

1998 640 citations Rolien de Jong, Frédéric Altare et al. Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frank P. Kroon Netherlands	31	1.9k	1.9k	1.0k	846	327	87	3.8k
Pompeyo Viciana Spain	31	1.1k 0.6×	1.7k 0.9×	403 0.4×	1.2k 1.4×	446 1.4×	131	2.9k
Pier‐Angelo Tovo Italy	42	1.9k 1.0×	1.8k 0.9×	1.1k 1.1×	1.2k 1.4×	833 2.5×	190	5.0k
Helmut Albrecht United States	31	1.0k 0.5×	1.4k 0.8×	493 0.5×	865 1.0×	153 0.5×	121	3.1k
Alejo Erice United States	38	2.9k 1.5×	1.7k 0.9×	612 0.6×	1.9k 2.2×	197 0.6×	84	4.8k
Christos Tsoukas Canada	26	840 0.4×	1.2k 0.6×	838 0.8×	1.1k 1.3×	245 0.7×	93	2.6k
B. Marchou France	35	1.2k 0.6×	2.3k 1.2×	524 0.5×	1.5k 1.7×	195 0.6×	144	3.8k
Eric Sandström Sweden	35	1.2k 0.6×	1.6k 0.9×	917 0.9×	1.7k 2.0×	132 0.4×	169	3.9k
Harold A. Kessler United States	39	2.0k 1.1×	2.6k 1.4×	1.1k 1.1×	2.8k 3.3×	346 1.1×	126	5.2k
Sergio Lo Caputo Italy	30	860 0.4×	1.7k 0.9×	896 0.9×	1.7k 2.0×	230 0.7×	147	3.2k
Eugenia Quirós-Roldán Italy	32	1.1k 0.6×	2.0k 1.1×	712 0.7×	1.1k 1.3×	589 1.8×	228	4.2k

Countries citing papers authored by Frank P. Kroon

Since Specialization

Citations

This map shows the geographic impact of Frank P. Kroon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank P. Kroon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank P. Kroon more than expected).

Fields of papers citing papers by Frank P. Kroon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank P. Kroon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank P. Kroon. The network helps show where Frank P. Kroon may publish in the future.

Co-authorship network of co-authors of Frank P. Kroon

This figure shows the co-authorship network connecting the top 25 collaborators of Frank P. Kroon. A scholar is included among the top collaborators of Frank P. Kroon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank P. Kroon. Frank P. Kroon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wijnen, Ben, Silvia Evers, Jan M. Prins, et al.. (2018). Cost-effectiveness and Cost-utility of the Adherence Improving Self-management Strategy in Human Immunodeficiency Virus Care: A Trial-based Economic Evaluation. Clinical Infectious Diseases. 68(4). 658–667. 7 indexed citations

Kloppenburg, M., Roberta Ramonda, Wing‐Yee Kwok, et al.. (2017). Randomised, placebo-controlled trial to evaluate clinical efficacy and structure modifying properties of subcutaneous etanercept in patients with erosive inflammatory hand osteoarthritis. Osteoarthritis and Cartilage. 25. S8–S8. 3 indexed citations

Smit, Colette, Frank P. Kroon, Pythia T. Nieuwkerk, et al.. (2017). A Survey of Patients’ Perspectives on Outpatient HIV Care in the Netherlands. Infectious Diseases and Therapy. 6(3). 443–452. 6 indexed citations

Smit, Colette, Ard van Sighem, Peter Reiss, et al.. (2015). Impact of HIV care facility characteristics on the cascade of care in HIV-infected patients in the Netherlands. AIDS. 30(2). 301–310. 10 indexed citations

Lelyveld, S.F.L. van, Julia Drylewicz, Sigrid A. Otto, et al.. (2015). Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial. PLoS ONE. 10(7). e0132430–e0132430. 26 indexed citations

Bickel, Markus, Imke Wieters, Frank P. Kroon, et al.. (2014). Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients. Scandinavian Journal of Infectious Diseases. 46(9). 656–659. 2 indexed citations

Zoutendijk, Roeland, Hans L. Zaaijer, T.E.M.S. de Vries-Sluijs, et al.. (2012). Hepatitis B Surface Antigen Declines and Clearance During Long-Term Tenofovir Therapy in Patients Coinfected With HBV and HIV. The Journal of Infectious Diseases. 206(6). 974–980. 60 indexed citations

Boer, Mark de, Frank P. Kroon, Saskia le Cessie, Johan W. de Fijter, & Jaap T. van Dissel. (2011). Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transplant Infectious Disease. 13(6). 559–569. 59 indexed citations

Steingrover, Radjin, Irene G. M. van Valkengoed, Vincent Bekker, et al.. (2010). Transient Lowering of the Viral Set Point After Temporary Antiretroviral Therapy of Primary HIV Type 1 Infection. AIDS Research and Human Retroviruses. 26(4). 379–387. 20 indexed citations

10.

Schellens, Ingrid M. M., Katalin Pogány, Geertje H. A. Westerlaken, et al.. (2010). Immunological Analysis of Treatment Interruption After Early Highly Active Antiretroviral Therapy. Viral Immunology. 23(6). 609–618. 1 indexed citations

11.

Boer, Mark de, Els Wessels, Eric C. J. Claas, & Frank P. Kroon. (2010). Potential Influence of More-Sensitive HIV-1 Load Detection by the new Roche Cobas AmpliPrep/Cobas TaqMan Version 2.0 Assay on Clinical Management of HIV-Positive Pregnant Women. Journal of Clinical Microbiology. 48(11). 4301–4302. 7 indexed citations

12.

Gelinck, L. B. S., et al.. (2008). [Practical advice for travellers with immune disorders].. PubMed. 152(31). 1725–9. 3 indexed citations

13.

Pogány, Katalin, Irene G. M. van Valkengoed, Jan M. Prins, et al.. (2007). Effects of Active Treatment Discontinuation in Patients With a CD4+ T-Cell Nadir Greater Than 350 Cells/mm3. JAIDS Journal of Acquired Immune Deficiency Syndromes. 44(4). 395–400. 27 indexed citations

14.

Sankatsing, Raaj R., Emile F. Schippers, Martin Vogel, et al.. (2007). Pharmacokinetics and Pharmacodynamics of Combined use of Lopinavir/Ritonavir and Rosuvastatin in HIV-Infected Patients. Antiviral Therapy. 12(7). 1127–1132. 65 indexed citations

15.

Burger, David M., Patricia W. H. Hugen, Peter Reiss, et al.. (2003). Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 17(8). 1157–1165. 119 indexed citations

16.

Schippers, Emile F., Patricia W. H. Hugen, Ruud J. R. Den Hartigh, et al.. (2000). No drug–drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients. AIDS. 14(17). 2794–2795. 13 indexed citations

17.

Pakker, Nadine G., Marijke Roos, Sigrid A. Otto, et al.. (1999). Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. AIDS. 13(2). 203–212. 87 indexed citations

18.

Jong, Rolien de, Frédéric Altare, Inez-Anne Haagen, et al.. (1998). Severe Mycobacterial and Salmonella Infections in Interleukin-12 Receptor-Deficient Patients. Science. 280(5368). 1435–1438. 640 indexed citations breakdown →

19.

Burger, David M., Pieter L. Meenhorst, Chris H.H. ten Napel, et al.. (1995). Limited sampling models for the antiretroviral agent didanosine. European Journal of Pharmaceutical Sciences. 3(1). 7–13. 1 indexed citations

20.

Kroon, Frank P., et al.. (1994). Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS. 8(4). 469–476. 186 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact